NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
Sep 12, 2019
Catalent, today announced that professor David Schaffer has been appointed to the advisory board of the company’s biologics business.
Flexible Filling And Adoption Of ‘Ready-to-Use’ Technologies To Be Discussed By Catalent Biologics At The Pharma Forum
Sep 10, 2019
Catalent today announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum, to be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18 – 19, 2019.
Novavax and Catalent Announce Closing of Strategic Partnership
Jul 31, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing partner for gene therapies, today announced the closing of their previously announced arrangement.
Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
Jul 16, 2019
Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).
Catalent’s Partner, Passage Bio, Announces New Dedicated Gene Therapy Manufacturing Suite
Jul 10, 2019
The dedicated cGMP suite is to be built under strategic partnership with Paragon Gene Therapy to support future clinical and commercial production for Passage Bio’s AAV-delivered gene therapies
Catalent’s Partner, Amicus, Announces It Has Entered Into A Strategic Partnership With Catalent For Gene Therapy Development And Manufacturing
Jul 2, 2019
The agreement supports clinical and commercial supply needs for Pompe and other lysosomal disease gene therapy programs
The Use of Continuous Chromatography in Effective Process Design to be Presented by Catalent Biologics Expert at PREP Symposium
Jul 2, 2019
Catalent today announced that Ben Kester, Manager and Senior Scientist, Purification Development, Catalent Biologics, will present at the upcoming 32nd International Symposium on Preparative and Process Chromatography (PREP Symposium).
Novavax and Catalent Biologics Enter Strategic Partnership with Acquisition of Novavax’ Manufacturing Assets and Capabilities
Jun 27, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit today announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art…
Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy
Jun 19, 2019
Bristol-Myers Squibb Company and Catalent, Inc. today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
CPhI Worldwide
Date: November 5-7, 2019
World Orphan Drug Congress Europe
Date: November 12-14, 2019
Cell Therapy & Gene Therapy Manufacturing Congress 2019
Date: December 4-6, 2019
DDL 2019
Date: December 11-13, 2019
Phacilitate
Date: January 22-25, 2020
CASSS WCBP
Date: January 28-30, 2020
CASSS BIOASSAY
Date: March 23-25, 2020
ISBiotech Spring
Date: March 23-25, 2020
Gene Therapy for Rare Disorders
Date: March 30 – April 2, 2020
BEBPA Bioassay Conference
Date: March 25-27, 2020
World Vaccine Congress
Date: April 7-9, 2020
Interphex
Date: April 28-30, 2020
PEGS Boston
Date: May 4 – 8, 2020
BEBPA HCP
Date: May 13-15, 2020
BIO International Convention
Date: June 8 – 11, 2020